[1] 杨樟,徐祖才.预防性抗癫痫药物治疗研究进展[J].重庆医科大学学报,2016,41(1):5-7.
[2] 严峻,高作惠,龚传鹏,等.喹硫平联合丙戊酸钠对首发性精神分裂症伴有冲动与攻击行为患者兴奋躁动的影响[J].东南大学学报(医学版),2015,34(4):148-150.
[3] 丁媛媛,杨凡,刘静,等.多药耐药基因单倍体对中国癫痫患者丙戊酸钠血药浓度的影响[J].中国临床药理学与治疗学,2010,15(11):1267-1272.
[4] 李甲,陈宝安.抑制P-糖蛋白转运体功能在逆转肿瘤多药耐药中的研究现状及进展[J].东南大学学报(医学版),2018,37(2):359-363.
[5] JUAN-TOGORES J M,WILLIAM G.Lennox and the International Anti-Epilepsy League:a description of his life and work[J].Revista De Neurologia,1998,26(154):1074-1075.
[6] 庹虎,姚宝珍,刘小雪,等.癫痫患儿行为障碍及影响因素分析[J].现代医学,2014,42(1):30-33.
[7] 陈娟,王雪丁,周列民,等.转运体基因多态性对癫痫患者丙戊酸血药浓度及临床疗效的影响[J].中国临床药理学杂志,2016,32(3):215-217.
[8] CUFFE S,AZAD A K,QIU X,et al.ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients[J].Cancer Epidemiology,2016,41(4):50-56.
[9] 王丹,魏玉辉,周燕,等.基于多药耐药相关蛋白2(Abcc2/Mrp2)在大鼠肾脏表达性别差异的氧氟沙星药动学变化[J].药学学报,2012,47(5):624-629.
[10] 韩志刚,马玲,陶洁,等.新疆维吾尔族晚期非小细胞肺癌GSTP1、ABCC2基因多态性与含铂方案化疗敏感性的研究[J].临床肿瘤学杂志,2015,20(1):23-29.
[11] GROVER S,KUKRETI R.A systematic review and meta-analysis of the role of ABCC2,variants on drug response in patients with epilepsy[J].Epilepsia,2013,54(5):936-945.
[12] AKIYAMA Y,FUJITA K,ISHIDA H,et al.Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer[J].Drug Metab Pharmacokinet,2012,27(3):325-335.
[13] MA C L,WU X Y,JIAO Z,et al.SCN1A,ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy[J].Pharmacogenomics,2015,16(4):347-360.
[14] 张致庆,徐虹.基因多态性对儿童霉酚酸酯个体化治疗的意义[J].临床儿科杂志,2018,38(5):259-261.
[15] 韩志刚,陶洁,王强,等.新疆地区维吾尔族和汉族晚期非小细胞肺癌患者三磷酸腺苷结合盒转运体C2基因多态性差异研究[J].实用心脑肺血管病杂志,2015,27(3):38-42.
[16] GARCÍA S G,RAMOS R D,NAZCO G C,et al.Effect of UGT,SLCO,ABCB and ABCC polymorphisms on irinotecan toxicity[J].Med Clin,2018,137(8):489-496.
[17] 刘思婷,李晓蕾,张永,等.ABCB1和ABCC2及SLCO1B1基因多态性与大剂量甲氨蝶呤化疗毒性作用的相关性[J].中华检验医学杂志,2014,37(1):60-65.
[18] ZHOU L,CAO Y,LONG H,et al.ABCB1,ABCC2,SCN1A,SCN2A,GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population[J].Die Pharmazie,2015,70(6):416-420.
[19] 李银英,张涛志.ABCC2-24C>T基因多态性对中国癫痫患者卡马西平剂量和血药浓度的影响[J].中国实用神经疾病杂志,2016,19(8):75-77.
[20] DI F R,SIESTO R S,VALENTE D,et al.Current strategies to minimize toxicity of oxaliplatin:selection of pharmacogenomic panel tests[J].Anticancer Drugs,2013,24(10):1069-1078.
[21] ROSNER G L,PANETTA J C,INNOCENTI F,et al.Pharmacogenetic pathwayanalysis of irinotecan[J].Clin Pharmacol Ther,2008,84(5):393-402.
[22] SHA'ARI H M,HAERIAN B S,BAUM L,et al.ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts[J].Pharmacogenomics,2014,15(4):459-466.
[23] LOPEZ-LOPEZ E,GUTIERREZ-CAMINO A,ASTIGARRAGA I,et al.Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia[J].Pharmacogenomics,2016,17(7):731-741. |